comprehensive -WSS

comprehensive

author：leisure time 2025-08-23 06:50:52 - browse：718

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： White House Covid adviser calls on docs to combat misinformation

leisure time

WSS

The struggle to figure out which patients 'deserve' Wegovy

'A game

Transgender sports debate: Physicians say bans are health issue

David Liu startup to focus on CRISPR delivery

Covid’s new normal has set in amid another rise in cases

Patients, doctors press FTC to beef up hospital merger scrutiny

leisure time

comprehensive

entertainment

Peter Hotez and the public health issue of online harassment

What happened to the House vote on health price transparency?

ChatGPT in medicine: STAT answers readers' burning questions

FDA panel to weigh safety of artificial wombs for preterm births

Supreme Court strikes down use of affirmative action

Senate bill would ban some hospital facility fees

Cancer drug shortages should be causing more outrage

The unintended consequences of overturning Roe v. Wade

Sports medicine is finally prioritizing gender equality

Akili changes sales model for its ADHD video game treatment

hotspot

Midwives could help bridge maternal health disparities in the U.S.

'A game

Senate bill would ban some hospital facility fees

Midwives could help bridge maternal health disparities in the U.S.

Assistant physicians can help address the primary care shortage

FDA weighs limits of animal data in assessing artificial wombs

focus

leisure time

hotspot

focus